eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Letter to the Editor

Itraconazole as a new pharmacotherapy method in haemangiomas

Przemysław Gałązka
1
,
Kamil Leis
1
,
Ewelina Mazur
1
,
Laura Nowowiejska
2

1.
Department of Paediatric Haematology and Oncology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
2.
Department of Dermatology and Venereology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland 
Adv Dermatol Allergol 2021; XXXVIII (6): 1122-1123
Online publish date: 2022/01/07
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Early childhood haemangioma ranks as one of the most common childhood neoplasms. This type of birthmark occurs in about 5% of all infants, most often during the first through fifth months of age. These benign tumours can develop in both internal organs (e.g., the liver) and on the skin, which is a particularly frequent location [1]. Currently, the standard of treatment is pharmacotherapy with beta blockers. Propranolol is the most commonly prescribed beta blocker due to its high efficacy and safety profile confirmed by many studies. As an alternative, other beta blockers can be used, including atenolol, timolol, and imiquimod [1–3]. In case of no satisfactory effect after pharmacotherapy, laser therapy or surgical treatment may be recommended [1, 2].
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.